The overexpression of ZDHHC9 in pancreatic tumors inhibits host antitumor immunity, suggesting that downregulating ZDHHC9 may be a practical immunotherapeutic approach with anti-PD-L1 therapy for pancreatic cancer (134). Here, ZDHHC9 is linked to familial pancreatic carcinoma.